Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
09:56am, Monday, 23'rd Aug 2021
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2021 Results - Earnings Call Transcript
05:56am, Sunday, 08'th Aug 2021
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2021 Results - Earnings Call Transcript
GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference
07:08pm, Thursday, 27'th May 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2021 Virtual Healthcare C
Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
09:01am, Thursday, 20'th May 2021
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
GlycoMimetics A Buy On Potential 2022 AML Data
09:06am, Wednesday, 19'th May 2021
GlycoMimetics A Buy On Potential 2022 AML Data
3 Net Current Asset Value Stock Picks
12:59pm, Tuesday, 11'th May 2021
There are some investors who buy U.S.-listed stocks that are trading below their liquidation value because they believe they can gain from these kinds of investments after the market has reappraised t
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2021 Results - Earnings Call Transcript
12:07pm, Monday, 03'rd May 2021
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2021 Results - Earnings Call Transcript
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021
07:30am, Monday, 03'rd May 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2021 and highlighted recent company events. Cash and cash equiv
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
09:00am, Saturday, 10'th Apr 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new
GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 Meeting
04:30pm, Wednesday, 10'th Mar 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the interim analysis of a Phase 1b proof-of-concept study of GMI-1359, the Company's dua
Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund
03:14pm, Sunday, 07'th Mar 2021
Week In Review: OrbiMed Raises $800 Million For Its Fourth Asia Fund
GlycoMimetics, Inc.'s (GLYC) CEO Rachel King on Q4 2020 Results - Earnings Call Transcript
02:35pm, Tuesday, 02'nd Mar 2021
GlycoMimetics, Inc.'s (GLYC) CEO Rachel King on Q4 2020 Results - Earnings Call Transcript
GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
04:30pm, Friday, 26'th Feb 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More informa
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
04:30pm, Tuesday, 23'rd Feb 2021
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tue
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition disclosed new data reinforcin
